Literature DB >> 24166413

Serotonin 2C receptor antagonists induce fast-onset antidepressant effects.

M D Opal1, S C Klenotich1, M Morais2, J Bessa2, J Winkle3, D Doukas3, L J Kay4, N Sousa2, S M Dulawa1.   

Abstract

Current antidepressants must be administered for several weeks to produce therapeutic effects. We show that selective serotonin 2C (5-HT2C) antagonists exert antidepressant actions with a faster-onset (5 days) than that of current antidepressants (14 days) in mice. Subchronic (5 days) treatment with 5-HT2C antagonists induced antidepressant behavioral effects in the chronic forced swim test (cFST), chronic mild stress (CMS) paradigm and olfactory bulbectomy paradigm. This treatment regimen also induced classical markers of antidepressant action: activation of cAMP response element-binding protein (CREB) and induction of brain-derived neurotrophic factor (BDNF) in the medial prefrontal cortex (mPFC). None of these effects were induced by subchronic treatment with citalopram, a prototypical selective serotonin reuptake inhibitor (SSRI). Local infusion of 5-HT2C antagonists into the ventral tegmental area was sufficient to induce BDNF in the mPFC, and dopamine D1 receptor antagonist treatment blocked the antidepressant behavioral effects of 5-HT2C antagonists. 5-HT2C antagonists also activated mammalian target of rapamycin (mTOR) and eukaryotic elongation factor 2 (eEF2) in the mPFC, effects recently linked to rapid antidepressant action. Furthermore, 5-HT2C antagonists reversed CMS-induced atrophy of mPFC pyramidal neurons. Subchronic SSRI treatment, which does not induce antidepressant behavioral effects, also activated mTOR and eEF2 and reversed CMS-induced neuronal atrophy, indicating that these effects are not sufficient for antidepressant onset. Our findings reveal that 5-HT2C antagonists are putative fast-onset antidepressants, which act through enhancement of mesocortical dopaminergic signaling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24166413     DOI: 10.1038/mp.2013.144

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  53 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

Review 2.  Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test.

Authors:  Stephanie C Dulawa; Rene Hen
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

3.  Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats.

Authors:  Megan E Breuer; Lucianne Groenink; Ronald S Oosting; Herman G M Westenberg; Berend Olivier
Journal:  Biol Psychiatry       Date:  2006-12-04       Impact factor: 13.382

Review 4.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

5.  Scopolamine produces larger antidepressant and antianxiety effects in women than in men.

Authors:  Maura L Furey; Ashish Khanna; Elana M Hoffman; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

Review 6.  Signaling pathways underlying the rapid antidepressant actions of ketamine.

Authors:  Ronald S Duman; Nanxin Li; Rong-Jian Liu; Vanja Duric; George Aghajanian
Journal:  Neuropharmacology       Date:  2011-09-02       Impact factor: 5.250

7.  SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system.

Authors:  V Di Matteo; G Di Giovanni; M Di Mascio; E Esposito
Journal:  Neuropharmacology       Date:  1999-08       Impact factor: 5.250

Review 8.  Role of neurotrophic factors in the etiology and treatment of mood disorders.

Authors:  Ronald S Duman
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

9.  S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.

Authors:  Anne Dekeyne; Clotilde Mannoury la Cour; Alain Gobert; Mauricette Brocco; Françoise Lejeune; Florence Serres; Trevor Sharp; Annie Daszuta; Amélie Soumier; Mariusz Papp; Jean-Michel Rivet; Gunnar Flik; Thomas I Cremers; Olivier Muller; Gilbert Lavielle; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2008-06-04       Impact factor: 4.530

10.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

View more
  40 in total

1.  Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex.

Authors:  C Nocjar; K D Alex; A Sonneborn; A I Abbas; B L Roth; E A Pehek
Journal:  Neuroscience       Date:  2015-03-27       Impact factor: 3.590

2.  An Interaction between Serotonin Receptor Signaling and Dopamine Enhances Goal-Directed Vigor and Persistence in Mice.

Authors:  Matthew R Bailey; Olivia Goldman; Estefanía P Bello; Muhammad O Chohan; Nuri Jeong; Vanessa Winiger; Eileen Chun; Elke Schipani; Abigail Kalmbach; Joseph F Cheer; Peter D Balsam; Eleanor H Simpson
Journal:  J Neurosci       Date:  2018-01-24       Impact factor: 6.167

Review 3.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

4.  Improving temporal cognition by enhancing motivation.

Authors:  Billur Avlar; Julia B Kahn; Greg Jensen; Eric R Kandel; Eleanor H Simpson; Peter D Balsam
Journal:  Behav Neurosci       Date:  2015-08-10       Impact factor: 1.912

5.  A novel heat shock protein alpha 8 (Hspa8) molecular network mediating responses to stress- and ethanol-related behaviors.

Authors:  Kyle R Urquhart; Yinghong Zhao; Jessica A Baker; Ye Lu; Lei Yan; Melloni N Cook; Byron C Jones; Kristin M Hamre; Lu Lu
Journal:  Neurogenetics       Date:  2016-01-18       Impact factor: 2.660

6.  Evidence of an antidepressant-like effect of xylopic acid mediated by serotonergic mechanisms.

Authors:  Robert Peter Biney; Charles Kwaku Benneh; Donatus Wewura Adongo; Elvis Ofori Ameyaw; Eric Woode
Journal:  Psychopharmacology (Berl)       Date:  2021-04-10       Impact factor: 4.530

7.  Modulation of Monoaminergic Systems by Antidepressants in the Frontal Cortex of Rats After Chronic Mild Stress Exposure.

Authors:  David Martín-Hernández; Marta P Pereira; Hiram Tendilla-Beltrán; José L M Madrigal; Borja García-Bueno; Juan C Leza; Javier R Caso
Journal:  Mol Neurobiol       Date:  2019-05-03       Impact factor: 5.590

Review 8.  The influence of ketamine on drug discovery in depression.

Authors:  Christoph Kraus; Daniel Wasserman; Ioline D Henter; Elia Acevedo-Diaz; Bashkim Kadriu; Carlos A Zarate
Journal:  Drug Discov Today       Date:  2019-08-02       Impact factor: 7.851

9.  Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner.

Authors:  Kristina Holubova; Lenka Kleteckova; Martina Skurlova; Jan Ricny; Ales Stuchlik; Karel Vales
Journal:  Psychopharmacology (Berl)       Date:  2016-03-23       Impact factor: 4.530

10.  Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra.

Authors:  Mary V Burke; Christine Nocjar; Alex J Sonneborn; Andrew C McCreary; Elizabeth A Pehek
Journal:  J Neurochem       Date:  2014-08-21       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.